These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3784917)

  • 41. A comparison of serum oestrogen levels after percutaneous and oral administration of oestradiol-17 beta.
    Lyrenäs S; Carlström K; Bäckström T; von Schoultz B
    Br J Obstet Gynaecol; 1981 Feb; 88(2):181-7. PubMed ID: 7459307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study.
    Arabi A; Garnero P; Porcher R; Pelissier C; Benhamou CL; Roux C
    Hum Reprod; 2003 Aug; 18(8):1747-52. PubMed ID: 12871894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Body composition and bone mass in post-menopausal women.
    Compston JE; Bhambhani M; Laskey MA; Murphy S; Khaw KT
    Clin Endocrinol (Oxf); 1992 Nov; 37(5):426-31. PubMed ID: 1486693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating dehydroepiandrosterone-sulphate decreases even with a slight change in oestradiol.
    Matsui S; Yasui T; Kasai K; Yoshida K; Kato T; Uemura H; Kuwahara A; Matsuzaki T; Irahara M
    J Obstet Gynaecol; 2018 Feb; 38(2):231-235. PubMed ID: 28903616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma oestrogens in postmenopausal women with endometrial cancer.
    Nyholm HC; Nielsen AL; Lyndrup J; Dreisler A; Hagen C; Haug E
    Br J Obstet Gynaecol; 1993 Dec; 100(12):1115-9. PubMed ID: 8297845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women.
    Hänggi W; Lippuner K; Jaeger P; Birkhäuser MH; Horber FF
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):691-9. PubMed ID: 9713556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Trial prevention of mammary epithelioma metastases by a progestagen-estrogen combination].
    Jayle MF; Chemama R; Ennuyer A; Dhermain P; Plouchart A
    Bull Cancer; 1976; 63(3):379-86. PubMed ID: 793653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment options and menopause regimens.
    Farrell E
    Aust Fam Physician; 1992 Mar; 21(3):240-6. PubMed ID: 1605762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oestrone sulphate in plasma from postmenopausal women and the effects of oestrogen and androgen therapy.
    Towobola OA; Crilly RC; Oakey RE
    Clin Endocrinol (Oxf); 1980 Nov; 13(5):461-71. PubMed ID: 6261992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
    van der Mooren MJ; Demacker PN; Thomas CM; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1992 Nov; 47(2):153-60. PubMed ID: 1459329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of endometrial cancer with progestogens.
    Gambrell RD
    Maturitas; 1986 Jul; 8(2):159-68. PubMed ID: 3747849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK; Governale LA
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review.
    Rijpkema AH; van der Sanden AA; Ruijs AH
    Maturitas; 1990 Sep; 12(3):259-85. PubMed ID: 2145495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Climacteric symptoms after oral and percutaneous hormone replacement therapy.
    Jensen PB; Jensen J; Riis BJ; Rødbro P; Strøm V; Christiansen C
    Maturitas; 1987 Nov; 9(3):207-15. PubMed ID: 2963205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of the role of progestogens in hormonal replacement therapy: influence on bleeding patterns.
    Fraser IS
    Maturitas; 1986 Jul; 8(2):113-21. PubMed ID: 3747847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial.
    Sites CK; L'Hommedieu GD; Toth MJ; Brochu M; Cooper BC; Fairhurst PA
    J Clin Endocrinol Metab; 2005 May; 90(5):2701-7. PubMed ID: 15687338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women.
    Jensen J; Riis BJ; Strøm V; Christiansen C
    Maturitas; 1989 Jun; 11(2):117-28. PubMed ID: 2547137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
    Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.